Recent News

• 09.10.2025 - September 10, 2025 12:30 PM EDT - September 10, 2025 1:00 PM EDT : Marker Therapeutics Fireside Chat – H.C. Wainwright Conference
• 09.10.2025 - September 10, 2025 12:30 PM EDT - September 10, 2025 1:00 PM EDT : Marker Therapeutics Fireside Chat – H.C. Wainwright Conference
• 08.28.2025 - Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
• 08.28.2025 - Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
• 08.26.2025 - Marker Therapeutics Webcast - APOLLO Data
• 08.26.2025 - Marker Therapeutics Webcast - APOLLO Data
• 08.26.2025 - Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma
• 08.26.2025 - Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma
• 08.12.2025 - Canaccord Genuity 45th Annual Growth Conference – Marker Tx Fireside Chat
• 08.12.2025 - Canaccord Genuity 45th Annual Growth Conference – Marker Tx Fireside Chat

Recent Filings

• 08.26.2025 - EX-99.1 EX-99.1
• 08.26.2025 - 8-K Current report
• 08.20.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 08.19.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 08.18.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.12.2025 - 8-K Current report
• 08.05.2025 - 424B7 Prospectus [Rule 424(b)(7)]